AXERT Drug Patent Profile
When do Axert patents expire, and what generic alternatives are available?
Axert is a drug marketed by Janssen Pharms and is included in one NDA.
The generic ingredient in AXERT is almotriptan malate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the almotriptan malate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Axert
A generic version of AXERT was approved as almotriptan malate by TEVA PHARMS USA on July 7th, 2015.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AXERT?
- What are the global sales for AXERT?
- What is Average Wholesale Price for AXERT?
Summary for AXERT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 75 |
| Patent Applications: | 4,032 |
| Drug Prices: | Drug price information for AXERT |
| What excipients (inactive ingredients) are in AXERT? | AXERT excipients list |
| DailyMed Link: | AXERT at DailyMed |
Paragraph IV (Patent) Challenges for AXERT
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| AXERT | Tablets | almotriptan malate | 6.25 mg and 12.5 mg | 021001 | 1 | 2005-12-08 |
US Patents and Regulatory Information for AXERT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharms | AXERT | almotriptan malate | TABLET;ORAL | 021001-001 | May 7, 2001 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Janssen Pharms | AXERT | almotriptan malate | TABLET;ORAL | 021001-002 | May 7, 2001 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for AXERT
See the table below for patents covering AXERT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 177080 | ⤷ Start Trial | |
| Australia | 4570793 | ⤷ Start Trial | |
| Australia | 661190 | ⤷ Start Trial | |
| Brazil | 1100061 | ⤷ Start Trial | |
| Brazil | 9305589 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for AXERT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0605697 | 2001 00005 | Denmark | ⤷ Start Trial | DKCTFF CA 2001 00005, 20010226, EXPIRES: 20150329 |
| 0605697 | SPC/GB01/008 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026 |
| 0605697 | SPC003/2001 | Ireland | ⤷ Start Trial | SPC003/2001: 20041230, EXPIRES: 20141222 |
| 0605697 | C00605697/01 | Switzerland | ⤷ Start Trial | FORMER OWNER: LABORATORIOS ALMIRALL, S.A., ES |
| 0605697 | 9/2001 | Austria | ⤷ Start Trial | PRODUCT NAME: ALMOTRIPTAN UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE; NAT. REGISTRATION NO/DATE: 1-23957, 1-23958 20010131; FIRST REGISTRATION: ES 62877 19991223 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch